

Edgar Filing: CYTOCLONAL PHARMACEUTICS INC /DE - Form 8-K

CYTOCLONAL PHARMACEUTICS INC /DE

Form 8-K

October 25, 2001

SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported) October 24, 2001

CYTOCLONAL PHARMACEUTICS INC.
(Exact name of registrant as specified in its charter)

Delaware (State or Other Jurisdiction of Incorporation)	00-26078 (Commission File Number)	75-2402409 (I.R.S. Employer Identification No.)
---	--------------------------------------	---

2110 Research Row
Suite 621
Dallas, Texas 75235

(Address of principal executive
offices including zip code)

(214) 353-2922

(Registrant's telephone number,
including area code)

N.A.
(Former name or former address, if changed since last report)

Item 5. Other Events.

Effective October 24, 2001, Cytoclonal Pharmaceuticals Inc. (the "Company") changed its name to eXegenics Inc. This change was effected under Delaware law in connection with the merger into the Company of its wholly owned subsidiary, eXegenics Inc. In addition, effective October 24, 2001, the Company's Nasdaq National Market symbol was changed to "EXEG." The information contained in the Press Release dated October 24, 2001, which is attached hereto as Exhibit 99.1, is incorporated herein by reference and the foregoing description of such transactions contemplated thereby are qualified in their entirety by reference to such exhibit.

Item 7. Financial Statements and Exhibits.

(c) Exhibits

Exhibit No.	Description
-------------	-------------

Edgar Filing: CYTOCLONAL PHARMACEUTICS INC /DE - Form 8-K

99.1

Press Release, dated October 24, 2001.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CYTOCLONAL PHARMACEUTICS INC.
(Registrant)

Dated: October 25, 2001

By: /s/ Ronald Lane Goode, Ph. D.

Ronald Lane Goode, Ph.D.
President and Chief Executive Officer

EXHIBIT INDEX

EXHIBIT
NUMBER

DESCRIPTION

99.1

Press Release, dated October 24, 2001.